EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Venues 16th March - Kempinski Hotel Corvinus Budapest Erzsébet tér 7-8, 1051 Budapest If you need a hotel room, please book via the official hotel website. http://www.kempinski.com/en/budapest/hotel-corvinus/welcome/ 17th March - Gerbeaud House 1051 Budapest [...]
EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Presentations Click on the names to download specific presentations or scroll to the bottom to get the whole pack. Introduction Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF Discovery: Real World Evidence as a Tool for Translation [...]
EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Report Whatever the power of digital technologies and no matter the size of the data mountains, the true potential of digitised or machine-readable information relating to health will not be realised without the key ingredient of trust. The IMI-EMIF [...]
IMI 1 GetReal closing meeting: ‘Delivering tools for real-world evidence development’ 24 November, 2016, Brussels Royal Flemish Academy of Belgium for Science and the Arts Slides Videos Pictures [...]
IMI 1 GetReal closing meeting: ‘Delivering tools for real-world evidence development’ 24 November, 2016, Brussels Royal Flemish Academy of Belgium for Science and the Arts Speakers Lucien Abenhaim, MD, PhD & Chairman, LASER Analytica Francesca Cerreta, Senior Scientific Officer, EMA Chris Chinn, Head of [...]
30th December, 2017
The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.
Organised in partnership with: Advanced Therapies – Opportunities and Challenges 14th November, London Click to download your copy of the report Supported by: [...]
Advanced Therapies – Opportunities and Challenges 14th November, London Presentations Click on the name of the speaker to download the slide deck Keynote Session: “The Future of Advanced Therapies” Peter Goodfellow, Scientific Advisor, Abingworth “Regenerating the Future, Again” Lord James O’Shaughnessy, [...]
Organised in partnership with: Advanced Therapies – Opportunities and Challenges 14th November, London Presentations Click on the name of the speaker to download the slide deck Keynote Session: “The Future of Advanced Therapies” Peter Goodfellow, [...]
Michaël Hocquemiller, PhD Scientific Director, Lysogene Michaël Hocquemiller is scientific director at Lysogene. He has 10 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and [...]